tradingkey.logo
搜索

ANI Pharmaceuticals Inc

ANIP
添加自选
79.240USD
-1.190-1.48%
收盘 07-31 16:00美东报价延迟15分钟
1.80B总市值
19.26市盈率 TTM

ANI Pharmaceuticals Inc

79.240
-1.190-1.48%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-1.48%

5天

+2.05%

1月

-4.59%

6月

-0.95%

今年开始到现在

+0.38%

1年

+23.95%

关键数据
79.650今开
80.380最高
205.18K成交量
19.26市盈率 TTM
7.42市盈率动
--股息TTM
0.91%换手率
80.430昨收
78.240最低
13.56M成交额
亏损市盈率静
3.52市净率
0.00%股息率 TTM
6.79%ROA
99.50052周最高
0.82量比
-20.15M净利润
22.47M总股本
4.1138每股收益TTM
0.45Beta
17.11%ROE
57.33052周最低
2.66%振幅
51.78%毛利率
1.80B总市值
-2.77回报/风险
1.96%风险率

TradingKey ANI Pharmaceuticals Inc股票评分

单位: USD 更新时间: 2026-07-31

操作建议

ANI Pharmaceuticals Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在药品行业排名10/155位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价109.29。中期看,股价处于平稳状态。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

ANI Pharmaceuticals Inc评分

相关信息

行业排名
10 / 155
全市场排名
38 / 4281
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
极度看好

ANI Pharmaceuticals Inc亮点

亮点风险
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
业绩高增长
公司营业收入稳步增长,连续3年增长81.46%
利润高增长
公司净利润处于行业前列,最新年度总收入883.37M美元
业绩转盈
公司业绩转盈,最新年度盈利美元
估值合理
公司最新PE估值19.26,处于3年历史合理位
机构加仓
最新机构持股23.15M股,环比增加0.25%
约翰·胡斯曼持仓
明星投资者约翰·胡斯曼持仓,最新持仓市值49.41K

分析师目标

根据 8 位分析师
买入
评级
109.286
目标均价
+37.92%
涨幅空间

ANI Pharmaceuticals Inc新闻

即将为您带来更多新闻,敬请期待。。。

收益预测

分析师评级

根据 8 位分析师
买入
评级
109.286
目标均价
+37.92%
涨幅空间
强力买入
买入
持有
卖出
强力卖出

同行比较

160
总数
6
中位数
9
平均值
公司名称
评级分布
分析师数
ANI Pharmaceuticals Inc
ANIP
8
安进
AMGN
38
Biogen Inc
BIIB
38
礼来
LLY
35
辉瑞
PFE
32
艾伯维
ABBV
32
1
2
3
...
32

技术指标

技术指标
卖出(4)
中性(3)
买入(0)
指标
数值
方向
MACD(12,26,9)
-0.000
卖出
RSI(14)
45.744
中性
STOCH(KDJ)(9,3,3)
60.257
中性
ATR(14)
2.299
高波动
CCI(14)
-17.640
中性
Williams %R
56.990
卖出
TRIX(12,20)
-0.172
卖出
StochRSI(14)
29.901
卖出
移动平均线
卖出(5)
中性(0)
买入(1)
指标
数值
方向
MA5
80.172
卖出
MA10
79.152
买入
MA20
80.837
卖出
MA50
81.115
卖出
MA100
79.439
卖出
MA200
81.244
卖出

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

ANI Pharmaceuticals Inc简介

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
公司代码ANIP
公司ANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
网址https://www.anipharmaceuticals.com/

公司股东

持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
其他
75.58%

常见问题

ANI Pharmaceuticals Inc(ANIP)的当前股价是多少?

ANI Pharmaceuticals Inc(ANIP)的当前股价是 79.24。

ANI Pharmaceuticals Inc的股票代码是什么?

ANI Pharmaceuticals Inc的股票代码是ANIP。

ANI Pharmaceuticals Inc股票的52周最高点是多少?

ANI Pharmaceuticals Inc股票的52周最高点是99.50。

ANI Pharmaceuticals Inc股票的52周最低点是多少?

ANI Pharmaceuticals Inc股票的52周最低点是57.33。

ANI Pharmaceuticals Inc的市值是多少?

ANI Pharmaceuticals Inc的市值是1.78B。

现在ANI Pharmaceuticals Inc(ANIP)的股票是买入、持有还是卖出?

根据分析师评级,ANI Pharmaceuticals Inc(ANIP)的总体评级为买入,目标价格为109.29。

ANI Pharmaceuticals Inc(ANIP)股票的每股收益(EPS TTM)是多少

ANI Pharmaceuticals Inc(ANIP)股票的每股收益(EPS TTM)是3.50。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有